XETRA - Delayed Quote • EUR
BRAIN Biotech AG (BNN.DE)
At close: April 25 at 5:36 PM GMT+2
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
No. of Analysts | -- | -- | 7 | 5 |
Avg. Estimate | 0 | 0 | -0.25 | -0.19 |
Low Estimate | 0 | 0 | -0.51 | -0.37 |
High Estimate | 0 | 0 | 0.1 | 0.12 |
Year Ago EPS | -- | -- | -0.25 | -0.25 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
No. of Analysts | -- | -- | 7 | 7 |
Avg. Estimate | -- | -- | 50.37M | 58.47M |
Low Estimate | -- | -- | 43M | 52M |
High Estimate | -- | -- | 58.3M | 67.6M |
Year Ago Sales | -- | -- | 38.39M | 50.37M |
Sales Growth (year/est) | -- | -- | 31.20% | 16.10% |
Earnings History
CURRENCY IN USD | ||||
---|---|---|---|---|
EPS Est. | -- | -- | -- | -- |
EPS Actual | -- | -- | -- | -- |
Difference | -- | -- | -- | -- |
Surprise % | -- | -- | -- | -- |
EPS Trend
CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
Current Estimate | 0 | 0 | -0.25 | -0.19 |
7 Days Ago | 0 | 0 | -0.25 | -0.19 |
30 Days Ago | 0 | 0 | -0.28 | -0.26 |
60 Days Ago | 0 | 0 | -0.29 | -0.26 |
90 Days Ago | 0 | 0 | -0.29 | -0.25 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Sep 2022) | Next Qtr. (Dec 2022) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | BNN.DE | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -- | -- | -- | 2.60% |
Next Qtr. | -- | -- | -- | 13.40% |
Current Year | 0.00% | -- | -- | 5.20% |
Next Year | 24.00% | -- | -- | 13.30% |
Next 5 Years (per annum) | -17.77% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker